RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Coffee and notepad

Press releases

2022

28 Nov 2022, 18:00 | Regulatory
· Data readout demonstrates a significantly superior capacity of imlifidase to rapidly reduce levels of donor-specific antibodies (DSAs) compared to plasma exchange (standard of care) in the five days following the start of the treatment.
· A total of 30 patients have been randomized 2:1 to either imlifidase or plasma exchange with a six-month follow up period.[1]
·…
20 Oct 2022, 08:00 | Regulatory

· Total Revenue of SEK 67m in the third quarter 2022
· Positive reimbursement decisions received in Poland and Scotland
· $70 million raised in non-dilutive financing
· Imlifidase included in ESOT guidelines published in Transplant International
30 Sep 2022, 08:00

· Award granted by internationally recognized Great Place to Work[®] institute.
· Certification based on company-wide survey completed by 99% of Hansa employees.
· Metrics related to trust in the company, credibility, pride and fairness, continue to be among those most highly rated by employees.
Load more
Coffee and notepad

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

Thank you. You will get an e-mail message to activate your subscription.